Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OH › Cincinnati › NPI 1134165970
Lab

Labone of Ohio INC

Labone of Ohio INC was paid $167.17M by Medicaid between Jan 2018 and Dec 2024, across 423 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 12% of everything it billed.

33Billing provider infoLABONE OF OHIO INC
CINCINNATI, OH 45237
33aNPI1134165970assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$167.17M
24GClaims11,892,402
24DCodes billed423
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Ohio

Rank by total paid#2 of 116
Median peer was paid$313K
This provider vs. median535×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M$3.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20182,252,574$27.03M
20192,128,319$29.38M
20201,633,730$25.17M
20211,655,944$28.81M
20221,546,586$23.20M
20231,528,294$19.44M
2024incomplete1,146,955$14.14M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 12% 597,006 363,413 $19.91M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 11% 326,499 220,168 $17.99M
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 4.5% 114,629 105,627 $7.59M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 2.8% 237,850 221,572 $4.70M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 2.8% 235,705 219,388 $4.69M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 2.8% 67,434 41,724 $4.67M
80053 Comprehensive metabolic panel 2.6% 664,133 625,822 $4.37M
80061 Lipid panel 2.4% 486,486 462,243 $4.03M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 2.3% 88,491 83,171 $3.86M
84443 Thyroid stimulating hormone (TSH) 2.3% 359,985 342,653 $3.86M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 2.1% 204,600 193,570 $3.48M
80050 General health panel 2.0% 130,896 122,433 $3.33M
411 more codes
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.8% 196,239 $2.97M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 1.6% 9,866 $2.75M
87799 1.6% 115,438 $2.61M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.5% 147,935 $2.51M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.5% 488,963 $2.45M
87522 Neg quan hep c or qual rna 1.2% 83,963 $2.08M
80362 1.2% 171,690 $2.02M
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 1.2% 9,044 $1.93M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1.1% 20,732 $1.91M
80074 1.1% 72,542 $1.91M
87902 1.1% 12,377 $1.90M
80355 1.1% 212,711 $1.83M
86480 1.1% 49,290 $1.83M
80348 <1% 184,302 $1.67M
82607 <1% 166,669 $1.60M
83036 Hemoglobin; glycosylated (A1C) <1% 262,115 $1.49M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 12,392 $1.36M
86803 <1% 149,971 $1.32M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 12,193 $1.30M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 58,743 $1.24M
80373 <1% 140,619 $1.18M
87086 Culture, bacterial; quantitative colony count, urine <1% 225,264 $1.18M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 70,433 $1.16M
87512 <1% 43,374 $1.12M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 53,660 $1.12M
80354 <1% 127,515 $1.11M
80346 <1% 80,003 $1.09M
87088 <1% 181,372 $987K
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 4,633 $946K
80361 <1% 79,909 $937K
81513 <1% 33,744 $900K
82746 <1% 96,398 $886K
80368 <1% 102,261 $857K
83013 <1% 18,981 $837K
80349 <1% 98,636 $773K
80081 <1% 17,584 $766K
36415 Collection of venous blood by venipuncture <1% 521,205 $754K
80360 <1% 91,570 $749K
86003 <1% 15,302 $676K
82728 <1% 71,469 $621K
80366 <1% 64,287 $594K
80369 <1% 67,210 $580K
80324 <1% 69,833 $565K
87340 <1% 90,651 $560K
84439 <1% 92,367 $543K
87070 <1% 89,522 $516K
84403 <1% 31,507 $515K
80321 <1% 48,445 $495K
80353 <1% 62,602 $490K
80356 <1% 58,815 $463K
80365 <1% 63,885 $462K
87186 <1% 75,709 $438K
85027 <1% 106,538 $435K
86696 <1% 29,512 $410K
80358 <1% 52,037 $410K
84153 <1% 35,070 $401K
86235 <1% 9,571 $398K
80372 <1% 43,557 $395K
87077 <1% 70,505 $392K
86706 <1% 54,065 $374K
86704 <1% 47,197 $366K
83550 <1% 65,949 $360K
83655 <1% 42,429 $356K
83970 <1% 11,758 $313K
83540 <1% 74,016 $311K
86592 <1% 115,396 $307K
82652 <1% 14,545 $307K
80345 <1% 38,680 $294K
86708 <1% 35,263 $283K
80048 Basic metabolic panel (calcium, ionized) <1% 54,502 $282K
82570 <1% 118,017 $280K
81596 <1% 7,186 $262K
80359 <1% 35,011 $260K
84702 <1% 28,178 $258K
86695 <1% 28,190 $256K
86038 <1% 31,724 $255K
82043 <1% 67,235 $250K
83001 <1% 19,739 $240K
83735 <1% 57,562 $238K
87081 <1% 53,820 $235K
82670 <1% 13,292 $235K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 16,361 $234K
86787 <1% 27,289 $234K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 10,096 $234K
84436 <1% 54,704 $229K
80371 <1% 23,452 $224K
84402 <1% 13,604 $222K
86769 <1% 5,676 $218K
84481 <1% 19,919 $218K
87480 <1% 15,539 $201K
87510 <1% 15,525 $200K
80335 <1% 21,525 $197K
87660 <1% 15,577 $196K
84479 <1% 46,986 $189K
84146 <1% 14,904 $186K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 5,011 $183K
86780 <1% 23,519 $182K
88142 <1% 12,953 $170K
80076 <1% 33,670 $168K
83002 <1% 13,514 $164K
83880 <1% 7,276 $158K
81001 <1% 72,096 $152K
80323 <1% 10,962 $150K
86762 <1% 19,596 $149K
82248 <1% 43,240 $135K
87563 <1% 6,314 $134K
87147 <1% 35,850 $131K
82105 <1% 12,003 $130K
86317 <1% 13,117 $122K
81025 <1% 27,095 $118K
86376 <1% 11,697 $115K
88141 <1% 10,510 $114K
84144 <1% 8,442 $112K
83992 <1% 12,215 $108K
86200 <1% 12,185 $107K
84681 <1% 8,211 $104K
80374 <1% 12,595 $104K
83698 <1% 3,831 $102K
83525 <1% 13,585 $101K
83704 <1% 4,775 $97K
86705 <1% 13,270 $97K
86431 <1% 24,311 $93K
86665 <1% 4,612 $93K
86140 <1% 29,346 $93K
82627 <1% 6,483 $93K
83520 <1% 10,484 $88K
83690 <1% 19,175 $88K
84550 <1% 29,128 $87K
87209 <1% 7,387 $86K
86800 <1% 7,649 $80K
84480 <1% 10,248 $80K
87517 <1% 2,861 $80K
83516 <1% 9,668 $77K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 3,202 $76K
84270 <1% 5,405 $74K
87631 <1% 814 $73K
82785 <1% 6,178 $72K
82784 <1% 8,593 $70K
82150 <1% 16,245 $69K
86765 <1% 8,343 $68K
86735 <1% 8,195 $67K
84100 <1% 23,006 $67K
87536 <1% 1,299 $67K
82951 <1% 8,016 $66K
85610 <1% 25,619 $65K
84703 <1% 12,706 $64K
86850 <1% 15,787 $64K
85652 <1% 35,365 $63K
86709 <1% 8,442 $63K
87650 <1% 5,134 $62K
86160 <1% 4,263 $62K
81443 <1% 314 $61K
87075 <1% 9,586 $59K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 2,527 $56K
86141 <1% 6,299 $56K
84425 <1% 4,164 $56K
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 4,327 $56K
82550 <1% 12,884 $54K
86225 <1% 5,785 $53K
82950 <1% 17,723 $53K
87481 <1% 4,721 $51K
86364 <1% 2,786 $49K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 5,381 $47K
83021 <1% 3,737 $45K
80363 <1% 2,764 $45K
82672 <1% 3,124 $45K
G0475 Hiv antigen/antibody, combination assay, screening <1% 3,088 $45K
83695 <1% 5,065 $43K
83721 <1% 9,731 $43K
80164 <1% 4,906 $43K
87177 <1% 7,429 $43K
86039 <1% 5,755 $42K
82140 <1% 4,372 $42K
87255 <1% 1,848 $42K
83014 <1% 7,601 $41K
87625 <1% 3,039 $41K
80338 <1% 3,058 $41K
81003 <1% 53,709 $41K
82542 <1% 3,265 $39K
86664 <1% 3,630 $39K
82172 <1% 3,406 $38K
82977 <1% 7,870 $37K
86255 <1% 6,158 $37K
82677 <1% 1,844 $35K
82533 <1% 3,183 $34K
80325 <1% 5,404 $33K
87205 <1% 11,613 $32K
84154 <1% 2,787 $31K
80332 <1% 3,539 $31K
86147 <1% 1,830 $31K
84156 <1% 12,803 $30K
81329 <1% 844 $29K
86757 <1% 1,342 $28K
83020 <1% 3,987 $28K
86618 <1% 2,424 $28K
82465 <1% 8,560 $27K
83921 <1% 2,280 $27K
83498 <1% 1,519 $26K
84207 <1% 1,470 $26K
82565 <1% 7,987 $26K
87427 <1% 3,227 $25K
85018 <1% 16,366 $25K
85730 <1% 7,531 $24K
83615 <1% 5,615 $24K
87045 <1% 3,706 $24K
82274 <1% 2,201 $23K
85060 <1% 2,715 $22K
86336 <1% 1,839 $22K
87338 <1% 2,300 $22K
86901 <1% 13,139 $20K
86334 <1% 1,423 $20K
84466 <1% 2,393 $19K
86900 <1% 13,052 $19K
83519 <1% 2,117 $19K
86341 <1% 1,797 $19K
87449 <1% 2,779 $19K
80367 <1% 2,929 $18K
86617 <1% 1,334 $18K
84460 <1% 5,469 $18K
36416 <1% 11,185 $18K
80178 <1% 4,162 $18K
87329 <1% 2,299 $17K
84478 <1% 4,331 $17K
86146 <1% 1,030 $17K
86381 <1% 755 $16K
85045 <1% 5,855 $16K
86008 <1% 1,859 $15K
82310 <1% 4,785 $15K
84450 <1% 4,704 $15K
80177 <1% 1,678 $15K
82024 <1% 651 $15K
83090 <1% 1,449 $15K
87076 <1% 2,188 $15K
84165 <1% 2,047 $15K
85014 <1% 9,069 $14K
87046 <1% 2,012 $14K
86648 <1% 1,618 $14K
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician <1% 1,868 $13K
82330 <1% 1,625 $13K
86774 <1% 1,636 $13K
80069 <1% 2,538 $12K
84520 <1% 5,156 $12K
86666 <1% 1,012 $12K
82947 <1% 4,968 $12K
82397 <1% 1,095 $12K
85041 <1% 6,152 $12K
81512 <1% 527 $12K
85007 <1% 5,272 $12K
80320 <1% 1,652 $12K
82247 <1% 3,700 $12K
83718 <1% 2,160 $11K
86593 <1% 4,094 $11K
82103 <1% 1,312 $11K
87324 <1% 1,397 $11K
85379 <1% 1,651 $11K
81243 <1% 1,200 $11K
84445 <1% 341 $11K
86015 <1% 774 $10K
87529 <1% 361 $10K
83883 <1% 946 $10K
84305 <1% 697 $10K
82040 <1% 3,130 $10K
82952 <1% 3,389 $9K
86337 <1% 702 $9K
86361 <1% 531 $9K
80185 <1% 896 $8K
86753 <1% 990 $8K
86258 <1% 141 $8K
81401 <1% 158 $8K
86021 <1% 804 $8K
84630 <1% 1,144 $8K
86036 <1% 470 $8K
83010 <1% 760 $7K
82626 <1% 415 $7K
86304 <1% 516 $7K
84075 <1% 2,305 $7K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 128 $7K
82390 <1% 998 $7K
82378 <1% 565 $7K
84132 <1% 2,226 $7K
84155 <1% 2,919 $7K
83521 <1% 160 $7K
85004 <1% 1,420 $6K
99199 Unlisted special service, procedure or report <1% 3,049 $6K
86870 <1% 493 $6K
84432 <1% 609 $6K
83993 <1% 473 $6K
85660 <1% 1,983 $6K
81511 <1% 122 $5K
82232 <1% 538 $5K
87800 <1% 567 $5K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 99 $5K
86702 <1% 795 $5K
80342 <1% 444 $5K
86596 <1% 118 $4K
86812 <1% 263 $4K
86382 <1% 205 $4K
85613 <1% 646 $4K
86060 <1% 807 $4K
82157 <1% 239 $4K
86631 <1% 245 $4K
82642 <1% 183 $4K
81015 <1% 1,985 $4K
86308 <1% 1,110 $4K
86682 <1% 839 $4K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 185 $4K
85048 <1% 1,973 $3K
81332 <1% 184 $3K
88342 <1% 117 $3K
84484 <1% 536 $3K
84482 <1% 264 $3K
84252 <1% 261 $3K
80051 <1% 757 $3K
86701 <1% 769 $3K
87106 <1% 478 $3K
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 156 $3K
84590 <1% 434 $3K
87350 <1% 396 $3K
87581 <1% 92 $3K
87486 <1% 92 $3K
84295 <1% 972 $3K
84446 <1% 340 $3K
80299 <1% 227 $3K
86360 <1% 84 $3K
87634 <1% 58 $3K
86632 <1% 254 $3K
80055 <1% 82 $3K
82088 <1% 101 $2K
86692 <1% 200 $2K
82435 <1% 815 $2K
87493 <1% 110 $2K
82747 <1% 187 $2K
82365 <1% 239 $2K
80156 <1% 183 $2K
82166 <1% 126 $2K
82374 <1% 616 $2K
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 54 $2K
86644 <1% 182 $2K
83625 <1% 241 $2K
87185 <1% 594 $2K
86707 <1% 240 $2K
81241 <1% 75 $2K
82552 <1% 173 $1K
84244 <1% 99 $1K
80171 <1% 127 $1K
86645 <1% 114 $1K
87535 <1% 84 $1K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 14 $1K
82985 <1% 144 $1K
87101 <1% 209 $1K
99499 <1% 24 $1K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 154 $1K
82180 <1% 181 $1K
82164 <1% 109 $979.00
82104 <1% 108 $977.04
83876 <1% 30 $971.60
84202 <1% 83 $757.58
82668 <1% 53 $728.00
86162 <1% 54 $698.32
85049 <1% 250 $649.75
80184 <1% 64 $617.80
87140 <1% 133 $613.30
85240 <1% 57 $609.66
85246 <1% 43 $594.67
84080 <1% 73 $558.84
82525 <1% 62 $548.95
87102 <1% 95 $540.47
80197 <1% 60 $514.50
84134 <1% 47 $497.75
89055 <1% 153 $471.40
84597 <1% 55 $460.14
80175 <1% 55 $448.96
87206 <1% 112 $426.60
83835 <1% 40 $402.23
82107 <1% 14 $390.88
86886 <1% 99 $376.23
86671 <1% 50 $375.36
87468 <1% 67 $368.00
87469 <1% 67 $368.00
86335 <1% 13 $332.22
87220 <1% 82 $286.62
87254 <1% 15 $284.77
85303 <1% 32 $283.86
85306 <1% 27 $283.54
85230 <1% 28 $282.02
87484 <1% 64 $276.76
87150 <1% 13 $271.03
83527 <1% 29 $269.47
85245 <1% 18 $240.16
86615 <1% 16 $231.99
82530 <1% 16 $209.67
81240 <1% 14 $203.48
99001 <1% 1,846 $173.74
86790 <1% 24 $152.29
87107 <1% 25 $146.13
85598 <1% 12 $125.93
82085 <1% 13 $125.59
86340 <1% 12 $125.39
80375 <1% 21 $110.40
80162 <1% 13 $104.22
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 13 $86.94
85651 <1% 37 $77.56
84591 <1% 27 $60.84
87467 <1% 12 $26.95
3049F 0% 4,915 $0.00
3048F 0% 7,629 $0.00
3044F 0% 8,741 $0.00
3052F 0% 468 $0.00
3051F 0% 890 $0.00
3046F 0% 875 $0.00
3050F 0% 3,791 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (SR. VP)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics IncorporatedClifton, NJ$637.74M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.